Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.49 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 13/20 | 0.49 |
| ▸ | JAK1 | P23458 | 13/20 | 0.49 |
| ▸ | TYK2 | P29597 | 13/20 | 0.49 |
| ▸ | JAK3 | P52333 | 13/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 3/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3128772 | 0.94 | EHMT2 (0.53) | EHMT2EHMT1JAK2JAK1TYK2 | |
| SCHEMBL3128582 | 0.90 | EHMT2 (0.50) | EHMT2EHMT1JAK2JAK1TYK2 | |
| SCHEMBL3248338 | 0.88 | EHMT2 (0.53) | EHMT2EHMT1JAK2JAK1TYK2 | |
| SCHEMBL3118396 | 0.87 | EHMT2 (0.48) | EHMT2EHMT1JAK2JAK1TYK2 | |
| SCHEMBL3131920 | 0.86 | KMT2A (0.50) | EHMT2EHMT1KIF11 | |
| SCHEMBL3132010 | 0.86 | PTGER4 (0.53) | EHMT2EHMT1 | |
| SCHEMBL16496702 | 0.86 | ALDH1A1 (0.53) | EHMT2EHMT1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL16497018 | 0.85 | EHMT2 (0.51) | EHMT2EHMT1JAK2JAK1TYK2 | |
| SCHEMBL16496060 | 0.85 | PTGER4 (0.52) | EHMT2EHMT1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL16496684 | 0.85 | EHMT2 (0.46) | EHMT2EHMT1CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | EHMT2 2665/4885EHMT1 2545/4885JAK2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.